Since the introduction of the Drug Shortage Prevention Act in January, our legislation has earned bipartisan support in Congress, and many of our colleagues have shown a willingness to put their heads together and come up with other important solutions. Our legislation has also earned the support of the American Society of Clinical Oncology, the American Society for Parenteral and Enteral Nutrition, the Hematology/Oncology Pharmacy Association and the American Hospital Association.
This is not a partisan issue and there is nothing partisan about our legislation, which is designed to get at the heart of some of the problems leading to drug shortages.
In the coming weeks, as Congress considers the Prescription Drug User Fee Authorization Act, we urge our colleagues to include the Drug Shortage Prevention Act in the comprehensive reauthorization package.
Congressional gridlock on other issues shouldn’t get in the way of lifesaving legislation to address problems such as drug shortages. We are working hard to ensure that it does not.